JCC:炎症性肠病患者的口服铁吸收能力与肠道炎症有关而非病变部位

2020-03-21 MedSci原创 MedSci原创

贫血在炎症性肠病[IBD]中很常见,其两个主要病因是缺铁性贫血[IDA]和慢性炎症性贫血[ACI]。炎症细胞因子引起的肠铁吸收受损被认为在ACI中起主要作用,

背景和目标:贫血在炎症性肠病[IBD]中很常见,其两个主要病因是缺铁性贫血[IDA]和慢性炎症性贫血[ACI]。炎症细胞因子引起的肠铁吸收受损被认为在ACI中起主要作用,因此,本项研究了旨在探讨不同的潜在疾病,疾病位置以及铁缺乏或贫血类型对有或没有炎症的成年IBD患者口服铁吸收的影响。

方法:这项研究是一项针对成人IBD [ n = 73]和健康对照组[ n = 22] 的比较性,单中心开放临床试验。基线参数包括血细胞计数,铁状态(铁蛋白,转铁蛋白,转铁蛋白饱和度,可溶性转铁蛋白受体,铁调素,血清铁),高敏感性C反应蛋白[hsCRP]和白介素6测定。使用一种含有567.7 mg铁[II]-甘氨酸-硫酸盐复合物的口服肠溶胶囊来测试铁的吸收。在摄入后60/90/120/180/240分钟分别测定患者血清铁含量。

结果:本项研究结果显示出铁吸收能力受炎症和贫血或铁缺乏症[ID]类型的影响,但不受潜在疾病类型或位置的影响。ACI组显示出比其他所有组明显更低的铁吸收能力。hsCRP水平[-0.387,p <0.001],IL-6 [-0.331,p = 0.006],铁蛋白[-0.531,p <0.001]和血清铁调素[-0.353,p = 0.003]与血清铁呈负相关,转铁蛋白在同一时间点显示正相关[0.379,p <0.001]。

结论:潜在的疾病类型和位置似乎对铁的吸收能力几乎没有影响,而对口服铁的缺乏反应与血清炎症标记密切相关。因此,在发炎的情况下铁的吸收能力显着降低。

原始出处:

Agül Aksan. Et al. Inflammation, but Not the Underlying Disease or Its Location, Predicts Oral Iron Absorption Capacity in Patients With Inflammatory Bowel Disease. Journal of Crohn's and Colitis.2020.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2003748, encodeId=f4312003e48b8, content=<a href='/topic/show?id=5962382458f' target=_blank style='color:#2F92EE;'>#口服铁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38245, encryptionId=5962382458f, topicName=口服铁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Mon Aug 31 18:40:18 CST 2020, time=2020-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414770, encodeId=ebca1414e70e6, content=<a href='/topic/show?id=af1a8169e60' target=_blank style='color:#2F92EE;'>#肠道炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81697, encryptionId=af1a8169e60, topicName=肠道炎症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f1f3086480, createdName=lancelotzzl, createdTime=Mon Mar 23 04:40:18 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547312, encodeId=6920154e31299, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Mon Mar 23 04:40:18 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600047, encodeId=0265160004e30, content=<a href='/topic/show?id=508e6e03203' target=_blank style='color:#2F92EE;'>#炎症性肠病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67032, encryptionId=508e6e03203, topicName=炎症性肠病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9fa18776644, createdName=huangshifeng, createdTime=Mon Mar 23 04:40:18 CST 2020, time=2020-03-23, status=1, ipAttribution=)]
    2020-08-31 许安
  2. [GetPortalCommentsPageByObjectIdResponse(id=2003748, encodeId=f4312003e48b8, content=<a href='/topic/show?id=5962382458f' target=_blank style='color:#2F92EE;'>#口服铁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38245, encryptionId=5962382458f, topicName=口服铁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Mon Aug 31 18:40:18 CST 2020, time=2020-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414770, encodeId=ebca1414e70e6, content=<a href='/topic/show?id=af1a8169e60' target=_blank style='color:#2F92EE;'>#肠道炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81697, encryptionId=af1a8169e60, topicName=肠道炎症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f1f3086480, createdName=lancelotzzl, createdTime=Mon Mar 23 04:40:18 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547312, encodeId=6920154e31299, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Mon Mar 23 04:40:18 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600047, encodeId=0265160004e30, content=<a href='/topic/show?id=508e6e03203' target=_blank style='color:#2F92EE;'>#炎症性肠病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67032, encryptionId=508e6e03203, topicName=炎症性肠病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9fa18776644, createdName=huangshifeng, createdTime=Mon Mar 23 04:40:18 CST 2020, time=2020-03-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2003748, encodeId=f4312003e48b8, content=<a href='/topic/show?id=5962382458f' target=_blank style='color:#2F92EE;'>#口服铁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38245, encryptionId=5962382458f, topicName=口服铁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Mon Aug 31 18:40:18 CST 2020, time=2020-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414770, encodeId=ebca1414e70e6, content=<a href='/topic/show?id=af1a8169e60' target=_blank style='color:#2F92EE;'>#肠道炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81697, encryptionId=af1a8169e60, topicName=肠道炎症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f1f3086480, createdName=lancelotzzl, createdTime=Mon Mar 23 04:40:18 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547312, encodeId=6920154e31299, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Mon Mar 23 04:40:18 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600047, encodeId=0265160004e30, content=<a href='/topic/show?id=508e6e03203' target=_blank style='color:#2F92EE;'>#炎症性肠病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67032, encryptionId=508e6e03203, topicName=炎症性肠病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9fa18776644, createdName=huangshifeng, createdTime=Mon Mar 23 04:40:18 CST 2020, time=2020-03-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2003748, encodeId=f4312003e48b8, content=<a href='/topic/show?id=5962382458f' target=_blank style='color:#2F92EE;'>#口服铁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38245, encryptionId=5962382458f, topicName=口服铁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Mon Aug 31 18:40:18 CST 2020, time=2020-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414770, encodeId=ebca1414e70e6, content=<a href='/topic/show?id=af1a8169e60' target=_blank style='color:#2F92EE;'>#肠道炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81697, encryptionId=af1a8169e60, topicName=肠道炎症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f1f3086480, createdName=lancelotzzl, createdTime=Mon Mar 23 04:40:18 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547312, encodeId=6920154e31299, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Mon Mar 23 04:40:18 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600047, encodeId=0265160004e30, content=<a href='/topic/show?id=508e6e03203' target=_blank style='color:#2F92EE;'>#炎症性肠病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67032, encryptionId=508e6e03203, topicName=炎症性肠病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9fa18776644, createdName=huangshifeng, createdTime=Mon Mar 23 04:40:18 CST 2020, time=2020-03-23, status=1, ipAttribution=)]

相关资讯

IBD:全反式维甲酸可抵消肠道炎症中的腹泻并抑制腺瘤表达

肠上皮中的Cl- / HCO 3 -交换泵——DRA已成为腹泻的一个重要的治疗靶点,全反式维甲酸(ATRA)是一种关键的维生素A代谢产物,之前曾证明它可以刺激DRA在肠上皮细胞中的表达。因此,本项研

Gastroenterology:炎症性肠病患者肠道菌群变化研究

研究证实炎症性肠病患者肠道部分细菌丰度存在差异

JCC: Cadherin-11是人类肠道纤维化的调节剂

尽管目前人们尚未完全了解克罗恩病[CD]中肠纤维缩窄形成的机制,但有研究显示成纤维细胞的活化和胶原蛋白的过度沉积有助于此类并发症的发展。在这里,研究人员研究了钙黏着蛋白(Cadherin-

Dig Liver Dis:小儿炎症性肠病患者使用免疫调节剂的长期结果

在新的生物制剂越来越获得认可的时代,我们需要重新评估免疫调节剂在小儿炎症性肠病(IBD)治疗中的地位。

JGH Open: 周末效应不影响炎症性肠病的治疗效果

周末效应是指医护人员由于感觉到周末的来临而导致周末前一天效率低下而导致病患预后恶化的假说。因此,本项研究的目的是评估IBD患者在周末和工作日治疗效果的差异。

Dig Liver Dis:炎症性肠病患者接受医学访谈对使用英夫利昔单抗决定的影响

为了减轻医疗保健支出的负担,有人建议在炎症性肠病(IBD)患者从英夫利昔单抗的起始者转为使用生物仿制药。本项研究旨在探索胃肠病学家访谈对IBD患者接受从英夫利昔单抗生物原药转向其生物仿制药CT-